agilon health, inc. (AGL) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company's earnings call presents a mix of positive and cautious elements. While there is optimism in revenue expectations and strategic initiatives, uncertainties in payer incentives and lack of clarity on AI risk adjustments temper enthusiasm. The market cap suggests moderate volatility, aligning with a neutral sentiment as the company navigates both growth opportunities and operational challenges.
Key Financial Performance
Medicare Advantage Membership 426,000 members at the end of Q1 2026 compared to 491,000 in Q1 2025, reflecting a year-over-year decrease. The decline was due to a measured approach to growth, market exits finalized as of January 1, 2026, and payer exits in certain markets resulting from disciplined and profitability-focused contracting efforts.
ACO REACH Membership 110,000 members in Q1 2026 compared to 114,000 in Q1 2025, showing a slight year-over-year decrease. No specific reasons for the decline were mentioned.
Revenue Approximately $1.42 billion in Q1 2026 compared to $1.53 billion in Q1 2025, a year-over-year decrease. The decline was driven by reduced membership, partially offset by constructive rates for 2026 from CMS benchmarks, favorable payer contracting benefits, and increased revenue from higher estimated risk scores.
Medical Margin $149 million in Q1 2026 compared to $128 million in Q1 2025, reflecting a year-over-year increase. This was driven by higher revenue and lower overall medical expenses in the quarter.
Adjusted EBITDA $54 million in Q1 2026 compared to $21 million in Q1 2025, a significant year-over-year increase. The improvement was attributed to higher medical margin, operational expense discipline, and favorable ACO REACH performance.
ACO REACH Adjusted EBITDA $27 million in Q1 2026, exceeding expectations by approximately $5 million. The favorable performance was driven by CMS' removal of fraudulent urinary catheter and suspect skin substitute costs from 2025 performance and corresponding benchmark changes.
Cash and Marketable Securities $303 million at the end of Q1 2026, with an additional $47 million of off-balance sheet cash held by ACO entities. The year-end cash position is expected to be at least $125 million.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Enhanced Data Pipeline: Improved actuarial visibility and earlier identification of trends, enabling better financial and operational alignment.
Congestive Heart Failure Program: Scaled across 90% of markets, improving early diagnosis rates and reducing inpatient first diagnosis rates to less than 5%.
Generative AI Integration: Integrated into clinical workflows to provide actionable insights, improving physician decision-making and patient care.
Dementia Program: Focused on early diagnosis and caregiver support, addressing the 50% of undiagnosed dementia patients.
ACO REACH Membership: Demonstrated strong performance with 110,000 members in Q1 2026, highlighting the strength of the model.
New Full Risk Contract: Signed in Q1 2026 in an existing market with a new payer, contributing to revenue growth.
Cost Management: Achieved favorable medical cost trends, with 2025 cost trends revised down to 6.2%.
Payer Contracting: Finalized 2026 contracts and began 2027 contracting with a focus on shared profitability and margin expansion.
Adjusted EBITDA: Increased to $54 million in Q1 2026, driven by operational discipline and improved data visibility.
AI-Enabled Technology Platform: Enhanced data capabilities and AI integration are driving earlier identification of opportunities and improved operational precision.
Clinical Pathways Expansion: Plans to scale COPD and lung health pathways, focusing on early identification and intervention.
Quality and Stars Performance: Embedded quality measures into clinical workflows, improving care gap identification and closure.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Membership Decline: Medicare Advantage membership decreased from 491,000 in Q1 2025 to 426,000 in Q1 2026, driven by market exits and payer exits due to profitability-focused contracting efforts.
Revenue Decline: Revenue decreased year-over-year from $1.53 billion in Q1 2025 to $1.42 billion in Q1 2026, primarily due to membership decline.
Cost Trends and Limited Claims Visibility: Limited visibility into paid claims for 2026 led to a conservative cost trend assumption of 7.4% for Q1 2026, reflecting potential risks in cost management.
Part D Costs: Additional reserves were required for 2025 Part D costs due to limited data visibility, creating financial uncertainty.
ACO REACH Membership Decline: ACO REACH membership declined from 114,000 in Q1 2025 to 110,000 in Q1 2026, indicating challenges in maintaining membership levels.
Market Exits: Previously disclosed market exits finalized as of January 1, 2026, impacted membership and revenue.
Fraudulent Claims Impact: CMS addressed fraudulent claims related to urinary catheter and suspect skin substitute claims for 2025, highlighting risks in claim integrity.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: The company has revised its full-year 2026 revenue guidance to approximately $5.7 billion, reflecting higher-than-expected revenue associated with increased risk scores and a new full-risk contract signed in Q1 2026.
Medical Margin Projections: The full-year 2026 medical margin is expected to be approximately $375 million, supported by improved data visibility, payer contracting improvements, and conservative cost trend assumptions.
Adjusted EBITDA: The company expects adjusted EBITDA of approximately $25 million for 2026, reflecting strong operational execution and favorable ACO REACH performance.
Cost Trends: The company maintains a full-year net cost trend outlook of 7% for 2026, with favorable medical cost trend development observed in the second half of 2025.
Clinical Pathways Expansion: Plans to scale COPD and broader lung health pathways through 2026, focusing on earlier identification of COPD, expanded lung cancer screenings, and increased use of advanced diagnostics.
Dementia Program Expansion: The company is rolling out a dementia program with enhanced caregiver models, structured early-stage pathways, and virtual diagnostics to address the 50% of dementia patients who go undiagnosed.
Quality and Stars Performance: The company expects continued improvement in quality and stars performance through deeper data integration, earlier intervention, and analytics to identify patients at risk of missing key quality measures earlier in the year.
ACO REACH and CMS Models: The company remains optimistic about the potential for driving value creation through ACO REACH and CMS models, with a focus on clinical and quality programs that improve outcomes and reduce costs.
2027 Payer Contracting: The company has finalized 2026 payer contracts and is beginning the 2027 payer contracting process, emphasizing shared profitability and durable margin expansion.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Why is the company maintaining its full-year guidance for ACO REACH EBITDA at $25 million to $30 million despite achieving $26.5 million in the quarter?
A:The $5 million benefit seen in the quarter was related to 2025 performance, specifically due to CMS backing out costs for suspect skin substitutes and urinary catheters. It is still early in the year to adjust REACH performance guidance.
Q:Are the efficiencies from AI incremental to the $35 million OpEx benefit projected for 2026?
A:AI programs are bifurcated into OpEx efficiencies and impacts on medical costs and revenue. Early impacts on OpEx are limited, with more significant effects expected on revenue and medical costs. The value from AI initiatives typically materializes later in the healthcare environment.
Q:Is the rollout of dementia and COPD pathways on track, and will it contribute to 2026 profitability?
A:Yes, the rollout is on track, and it is expected to add value to 2026 profitability. However, outcomes take time to show up in claims. The heart failure program, initiated a year ago, has shown positive outcomes, and similar results are anticipated for other programs.
Q:What governance changes are being implemented at the physician group level, and when might results be seen?
A:The focus is on working with payers to emphasize the value created by physicians, rather than governance changes within the groups. Collaborative efforts aim to improve contractual negotiations, with results expected over time.
Q:What is the outlook for ACO REACH client participation and economics for next year?
A:Details of the lead program are still being analyzed. The company expects to be successful in both the lead and MSSP programs, with positive financial contributions anticipated in 2027 and beyond.
Q:Can fiscal 2026 results be built upon for 2027, or is there a risk of a reset?
A:The company views fiscal 2026 results as a solid foundation for 2027. Active discussions for 2027 contracts are ongoing, and the focus remains on profitability and building on the current foundation.
Q:What were the sources of medical margin upside in the quarter versus guidance?
A:The variance of $26 million compared to guidance midpoint was driven by a $50 million full-year benefit from risk adjustment updates (half realized in Q1) and margin from a new contract modeled at breakeven for the year but contributing in Q1 due to seasonality.
Q:What are the 2027 payer contracting objectives, and how do they compare to 2026?
A:Objectives include increasing percent of premium, reducing Part D exposure (currently less than 15%), and carving out supplemental benefits. These objectives remain consistent with prior years, and productive conversations with payers are ongoing.
Q:What is the update on new geography entry expenses and their alignment with guidance?
A:New geography entry expenses are in line with expectations for the first quarter, with no significant deviations from the guidance.
Q:What categories are driving the 7.4% cost trend in Q1, and what is the full-year guidance?
A:The 7.4% cost trend in Q1 is driven by escalated Part B costs, Part D costs, and inpatient costs. Full-year guidance is 7% net, with limited paid claims visibility in Q1.
Q:How is the 50 bps tailwind from improved payer bids tracking year-to-date?
A:The $127 million full-year benefit from payer contracting was already executed and is flowing through Q1 results. Payers are focused on margin improvement, which aligns with the company's objectives.
Q:What is the update on group MA mix and its impact on guidance?
A:Group MA mix remains consistent with last year. Negotiations with payer contracts include all members, and the initial guidance accounts for this.
Q:Was there any prior year development (PYD) recognized in Q1, and what was the impact?
A:There was $12 million in PYD related to 2025 dates of service, but no flow-through benefit due to additional reserves added for Part D costs. Part D is reflected in revenue, offsetting the PYD benefit.
Q:What is the confidence level for expanding margins in 2027 given recent performance?
A:Confidence has increased due to strong Q1 performance in risk adjustment. The company believes it can offset the 1.12 normalization factor and achieve growth aligned with the 5.33% rate for 2027.
Q:What was attractive about the new risk contract with a payer, and what is its financial impact?
A:The new contract, in an existing market, represents $200 million in revenue and is modeled at breakeven margin for the year. It offers a multi-year opportunity for margin improvement.
Q:What is the potential impact of CMS's AI-inferred risk adjustment model in the lead program?
A:Details on the AI-inferred risk adjustment model are limited, making it difficult to assess its impact. The company will evaluate as more information becomes available.
Q:How is the opportunity to double payer incentive contributions in 2026 tracking?
A:The opportunity to double contributions exists, but it is too early to assess performance. The guidance assumes similar performance to 2025, with confidence in delivering superior quality.
Q:When will the company focus on expanding its member base and new partner pipeline?
A:The current focus is on in-market growth and execution. Embedded growth occurs as members turn 65 and enter Medicare Advantage. Expansion efforts will be considered in the future.
Q:Review of Unclear Management Responses
A:Management avoided providing direct answers or lacked clarity on the following questions:
1. "Why are you guys not expecting any further contribution for that business for the rest of the year?" - The response was vague, citing it being early in the year to adjust REACH performance guidance.
2. "How are you contemplating the eventual AI-inferred risk adjustment model in the lead program?" - Management stated there are limited details available, making it difficult to assess the impact.
3. "How is the opportunity to double payer incentive contributions in 2026 tracking?" - Management indicated it is too early to assess performance, providing no concrete update.
4. "When will the company focus on expanding its member base and new partner pipeline?" - The response was non-committal, emphasizing current focus on in-market growth without specifying a timeline for expansion.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI physician
Advantage addition
CHF
COPD lung
Investor Relations
PCP
President Investor
Vice President
access
burden caregiver
care burden
care gap
combination
complication
detection
diagnostics physician
engagement
failure patient
guideline
hospital
infrastructure physician
insight
intervention risk
margin expansion
mission
outcome patient
partnership
payer contracting
pharmacy
physician partner
physician quality
point care
population
quality measure
risk patient
space
strength model
therapy
validation
workflow
AGL Transcript
agilon health, inc. (AGL) Q1 2026 Earnings Call Transcript
Unknown5-6
The company's earnings call presents a mix of positive and cautious elements. While there is optimism in revenue expectations and strategic initiatives, uncertainties in payer incentives and lack of clarity on AI risk adjustments temper enthusiasm. The market cap suggests moderate volatility, aligning with a neutral sentiment as the company navigates both growth opportunities and operational challenges.
agilon health, inc. (AGL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-10
agilon health, inc. (AGL) Q4 2025 Earnings Call Transcript
Unknown2-26
The earnings call summary presents mixed signals: while there are improvements in cash position and some positive financial metrics, the overall financial performance remains negative with significant losses and cost trends. The Q&A section highlights concerns about cost trends and unclear management responses, which could weigh on investor sentiment. The company's strategic focus on cost reduction and improved payer contracts is promising, but the lack of clear guidance on certain issues tempers optimism. Considering the company's market cap, the stock price is likely to remain relatively stable, resulting in a neutral sentiment.
agilon health, inc. (AGL) Q3 2025 Earnings Call Transcript
Unknown11-4
The earnings call summary presents a mixed picture. While there are strategic plans for 2026, current issues like the negative impact of ACO REACH program changes and unclear management responses create uncertainty. The Q&A section highlights concerns about profitability and contract renewals, but also notes potential improvements in 2026. The market cap suggests moderate volatility, leading to a neutral sentiment as the stock may not significantly move in either direction over the next two weeks.
AGL Slides
AGL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
